Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUT5 | Q11128 | 1/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.53 |
| ▸ | KRAS | P01116 | 5/20 | 0.52 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.49 |
| ▸ | NT5E | P21589 | 1/20 | 0.49 |
| ▸ | RNASEL | Q05823 | 5/20 | 0.48 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.47 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.47 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26622070 | 0.94 | FUT5 (0.55) | FUT5TGM2KRASDCPSNT5E | |
| SCHEMBL26622052 | 0.92 | FUT5 (0.55) | FUT5TGM2KRASDCPSNT5E | |
| SCHEMBL26201452 | 0.92 | KRAS (0.50) | FUT5TGM2KRASDCPSNT5E | |
| SCHEMBL26212713 | 0.92 | KRAS (0.50) | FUT5TGM2KRASDCPSNT5E | |
| SCHEMBL26621974 | 0.92 | KRAS (0.50) | FUT5TGM2KRASDCPSNT5E | |
| SCHEMBL25584006 | 0.91 | TGM2 (0.62) | FUT5TGM2KRASDCPSNT5E | |
| SCHEMBL26622391 | 0.91 | RNASEL (0.55) | FUT5TGM2KRASRNASELP2RY2 | |
| SCHEMBL26622416 | 0.90 | RNASEL (0.54) | FUT5TGM2KRASRNASELP2RY2 | |
| SCHEMBL23997752 | 0.90 | TGM2 (0.60) | FUT5TGM2KRASDCPSNT5E | |
| SCHEMBL25584010 | 0.90 | TGM2 (0.60) | FUT5TGM2KRASDCPSNT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340009-A1 | COMPOUNDS FOR RNA CAPPING AND USES THEREOF | GUANGZHOU HENOVCOM BIOSCIENCE CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| WO-2023159930-A1 | COMPOUND FOR RNA CAPPING AND APPLICATION OF COMPOUND | 广州市恒诺康医药科技有限公司 | 2023-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340009-A1 | COMPOUNDS FOR RNA CAPPING AND USES THEREOF | RNGTT, RNMT, NSUN2 | FUT5 1516/4885TGM2 2548/4885KRAS 2017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.